Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
Article in Lung Cancer (February 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Article in Lung Cancer (February 2024)
Article in Frontiers in Oncology (January 2024)
Article in Pathology (December 2023)